Potential mechanisms for mortality reduction associated with combination antibiotic therapy among severely ill patients with pneumococcal bacteremia [2]

American Journal of Respiratory and Critical Care Medicine

Volumn 172, Issue 11, 2005, Pages 1472-1473

  Schwartz, David N ^a  

^a Jr Hospital of Cook County   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFTRIAXONE; CEPHALOSPORIN; MACROLIDE;

ANTIBIOTIC THERAPY; APACHE; BACTEREMIA; COMMUNITY ACQUIRED PNEUMONIA; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG CLEARANCE; HUMAN; LETTER; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; PRIORITY JOURNAL; PROTEIN BINDING; REDUCTION; RISK FACTOR; STREPTOCOCCUS INFECTION; SURVIVAL TIME;

ANTI-BACTERIAL AGENTS; BACTEREMIA; CRITICAL CARE; CRITICAL ILLNESS; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HUMANS; PNEUMOCOCCAL INFECTIONS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 30344452285     PISSN: 1073449X     EISSN: 1073449X     Source Type: Journal    
DOI: None     Document Type: Letter

References (10)

1. Baddour LM, Yu VL, Klugman KP, Feldman C, Ortqvist A, Rello J, Morris AJ, Luna CM, Snydman DR, Ko WC, et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004;170:440-444.
2. Mufson MA, Stanek RJ. Bacteremic pneumococcal pneumonia in one American city: a 20-year longitudinal study, 1978-1997. Am J Med 1999;107:34S-43S.
3. Waterer GW, SomesGW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001;161:1837-1842.
4. Martinez JA, Horcajada JP, Almela M, Marco F, Soriano A, García E, Marco MA, Torres A, Mensa J. Addition of amacrolide to a β-lactambased empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003;36:389-395.
5. van Dalen R, Vree TB. Pharmacokinetics of antibiotics in critically ill patients. Intensive Care Med 1990;16:S235-S238.
6. Joynt GM, Lipman J, Gomersall CD, Yound RJ, Wong ELY, Gin T. The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients. J Antimicrob Chemother 2001;47:421-429.
7. Reeves JH, Russell GM, Cade JF, McDonald M. Comparison of ceftriaxone with cefotaxime in serious chest infections. Chest 1989;96:1292-1297.
8. Lipman J, Wallis SC, Rickard CM, Fraenkel D. Low cefpirome levels during twice daily dosing in critically ill septic patients: pharmacokinetic modeling calls for frequent dosing. Intensive Care Med 2001;27:363-370.
9. Belzberg H, Zhu J, Cornwell EE, Murray JA, Sava J, Salim A, Velmahos GC, Gill MA. Imipenem levels are not predictable in the critically ill patient. J Trauma 2004;56:111-117.
10. Mohr JF, Wanger A, Rex JH. Pharmacokinetic/pharmacodynamic modeling can help guide targeted antimicrobial therapy for nosocomial gram-negative infections in critically ill patients. Diagn Microbiol Infect Dis 2004;48:125-130.